Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome

Abelin, 2017, Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction, Immunity, 46, 315, 10.1016/j.immuni.2017.02.007 Abu-Ghazaleh, 2022, Worldwide prevalence of Lynch syndrome in patients with colorectal cancer: systematic review and meta-analysis, Genet. Med., 24, 971, 10.1016/j.gim.2022.01.014 Albert-Vega, 2018, Immune functional assays, from custom to standardized tests for precision medicine, Front. Immunol., 9, 2367, 10.3389/fimmu.2018.02367 Bai, 2018, PHLAT: inference of high-resolution HLA types from RNA and whole exome sequencing, Methods Mol. Biol., 193, 10.1007/978-1-4939-8546-3_13 Ballhausen, 2020, The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution, Nat. Commun., 11, 4740, 10.1038/s41467-020-18514-5 Barnetson, 2006, Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer, N. Engl. J. Med., 354, 2751, 10.1056/NEJMoa053493 Bauer, 2013, T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer, Cancer Immunol. Immunother., 62, 27, 10.1007/s00262-012-1303-8 Bentzen, 2016, Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes, Nat. Biotechnol., 34, 1037, 10.1038/nbt.3662 Bogen, 2019, CD4(+) T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models, Cancer Immunol. Immunother., 68, 1865, 10.1007/s00262-019-02374-0 Bohaumilitzky, 2022, The different immune profiles of normal colonic mucosa in cancer-free lynch syndrome carriers and lynch syndrome colorectal cancer patients, Gastroenterology, 162, 907, 10.1053/j.gastro.2021.11.029 Bohaumilitzky, 2020, Implications of hereditary origin on the immune phenotype of mismatch repair-deficient cancers: systematic literature review, J. Clin. Med., 9, 10.3390/jcm9061741 Cafri, 2020, mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer, J. Clin. Invest., 130, 5976, 10.1172/JCI134915 Chandran, 2022, Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA, Nat. Med., 28, 946, 10.1038/s41591-022-01786-3 Chang, 2021, MHC multimer: a molecular toolbox for immunologists, Mol. Cell., 44, 328, 10.14348/molcells.2021.0052 Chang, 2018, Immune profiling of premalignant lesions in patients with lynch syndrome, JAMA Oncol., 4, 1085, 10.1001/jamaoncol.2018.1482 Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat. Biotechnol., 31, 213, 10.1038/nbt.2514 Clendenning, 2018, Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas, Fam. Cancer, 17, 91, 10.1007/s10689-017-0013-y Coley, 1891, II. Contribution to the knowledge of sarcoma, Ann. Surg., 14, 199, 10.1097/00000658-189112000-00015 Cortes-Ciriano, 2017, A molecular portrait of microsatellite instability across multiple cancers, Nat. Commun., 8, 10.1038/ncomms15180 D'Alise, 2022, Adenoviral-based vaccine promotes neoantigen-specific CD8(+) T cell stemness and tumor rejection, Sci. Transl. Med., 14 D'Alise, 2019, Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade, Nat. Commun., 10, 2688, 10.1038/s41467-019-10594-2 Dahlin, 2011, Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor, Mod. Pathol., 24, 671, 10.1038/modpathol.2010.234 de Miranda, 2012, Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases, Clin. Cancer Res., 18, 1237, 10.1158/1078-0432.CCR-11-1997 Dolgin, 2021, The tangled history of mRNA vaccines, Nature, 597, 318, 10.1038/d41586-021-02483-w Dolton, 2018, Optimized peptide-MHC multimer protocols for detection and isolation of autoimmune T-cells, Front. Immunol., 9, 1378, 10.3389/fimmu.2018.01378 Dominguez-Valentin, 2020, Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database, Genet. Med., 22, 15, 10.1038/s41436-019-0596-9 Duzagac, 2021, 13 Engel, 2012, Risks of less common cancers in proven mutation carriers with lynch syndrome, J. Clin. Oncol., 30, 4409, 10.1200/JCO.2012.43.2278 Fan, 2016, MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data, Genome Biol., 17, 178, 10.1186/s13059-016-1029-6 Faridi, 2018, In immunopeptidomics we need a sniper instead of a shotgun, Proteomics, 18, 10.1002/pmic.201700464 Fehlings, 2019, Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment, J. Immunother. Cancer, 7, 249, 10.1186/s40425-019-0695-9 Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 Gambini, 2022, 14 Garcia-Garijo, 2019, Determinants for neoantigen identification, Front. Immunol., 10, 1392, 10.3389/fimmu.2019.01392 Gebert, 2021, Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a lynch syndrome mouse model, Gastroenterology, 161, 1288, 10.1053/j.gastro.2021.06.073 2017 Giardiello, 2014, Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer, Gastroenterology, 147, 502, 10.1053/j.gastro.2014.04.001 GmbH Goldman, 2009, The cancer vaccine roller coaster, Nat. Biotechnol., 27, 129, 10.1038/nbt0209-129 Halstead, 2002, In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses, Nat. Immunol., 3, 536, 10.1038/ni798 Hause, 2016, Classification and characterization of microsatellite instability across 18 cancer types, Nat. Med., 22, 1342, 10.1038/nm.4191 Hernandez-Sanchez, 2022, Vaccines for immunoprevention of DNA mismatch repair deficient cancers, J. Immunother. Cancer, 10 Hilf, 2019, Actively personalized vaccination trial for newly diagnosed glioblastoma, Nature, 565, 240, 10.1038/s41586-018-0810-y Hodge, 2020, Recent developments in neoantigen-based cancer vaccines, Asian Pac. J. Allergy Immunol., 38, 91 Holter, 2022, Risk assessment and genetic counseling for lynch syndrome - practice resource of the national society of genetic counselors and the collaborative group of the americas on inherited gastrointestinal cancer, J. Genet. Counsel., 31, 568, 10.1002/jgc4.1546 Hudson, 2023, Can we predict T cell specificity with digital biology and machine learning?, Nat. Rev. Immunol., 10.1038/s41577-023-00835-3 Huh, 2012, Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer, Arch. Surg., 147, 366, 10.1001/archsurg.2012.35 Hundal, 2016, pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens, Genome Med., 8, 11, 10.1186/s13073-016-0264-5 Jiricny, 2006, The multifaceted mismatch-repair system, Nat. Rev. Mol. Cell Biol., 7, 335, 10.1038/nrm1907 Katsnelson, 2021, Preventive cancer vaccine based on neoantigens gets put to the test, ACS Cent. Sci., 7, 1288, 10.1021/acscentsci.1c00936 Keir, 2007, PD-1 and its ligands in T-cell immunity, Curr. Opin. Immunol., 19, 309, 10.1016/j.coi.2007.04.012 Keskin, 2019, Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial, Nature, 565, 234, 10.1038/s41586-018-0792-9 Kloor, 2005, Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers, Cancer Res., 65, 6418, 10.1158/0008-5472.CAN-05-0044 Kloor, 2012, Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study, Lancet Oncol., 13, 598, 10.1016/S1470-2045(12)70109-2 Kloor, 2020, A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial, Clin. Cancer Res., 26, 4503, 10.1158/1078-0432.CCR-19-3517 Kloor, 2016, The immune biology of microsatellite-unstable cancer, Trends Cancer, 2, 121, 10.1016/j.trecan.2016.02.004 Kodysh, 2020, OpenVax: an open-source computational pipeline for cancer neoantigen prediction, Methods Mol. Biol., 2120, 147, 10.1007/978-1-0716-0327-7_10 Koornstra, 2009, Fas ligand expression in lynch syndrome-associated colorectal tumours, Pathol. Oncol. Res., 15, 399, 10.1007/s12253-008-9136-7 Kunkel, 2015, Eukaryotic mismatch repair in relation to DNA replication, Annu. Rev. Genet., 49, 291, 10.1146/annurev-genet-112414-054722 Lai, 2016, VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research, Nucleic Acids Res., 44, e108, 10.1093/nar/gkw227 Larson, 2012, SomaticSniper: identification of somatic point mutations in whole genome sequencing data, Bioinformatics, 28, 311, 10.1093/bioinformatics/btr665 Laumont, 2016, Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames, Nat. Commun., 7, 10.1038/ncomms10238 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Leko, 2021, Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma, J. Immunother. Cancer, 9, 10.1136/jitc-2021-002882 Leoni, 2020, A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability, Cancer Res., 80, 3972, 10.1158/0008-5472.CAN-20-1072 Linnebacher, 2001, Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens, Int. J. Cancer, 93, 6, 10.1002/ijc.1298 Liu, 2018, WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia, Exp. Hematol. Oncol., 7, 1, 10.1186/s40164-018-0093-x Liu, 2021, Development and delivery systems of mRNA vaccines, Front. Bioeng. Biotechnol., 9 Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov., 5, 43, 10.1158/2159-8290.CD-14-0863 Lowery, 2022, Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers, Science, 375, 877, 10.1126/science.abl5447 Lu, 2022, dbPepNeo2.0: a database for human tumor neoantigen peptides from mass spectrometry and TCR recognition, Front. Immunol., 13 Lu, 2021, Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing, J. Immunother. Cancer, 9, 10.1136/jitc-2021-002595 Ma, 2012, De novo sequencing and homology searching, Mol. Cell. Proteomics, 11, 10.1074/mcp.O111.014902 Ma, 2021, High-throughput and high-dimensional single-cell analysis of antigen-specific CD8(+) T cells, Nat. Immunol., 22, 1590, 10.1038/s41590-021-01073-2 Mardis, 2019, Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response, Genome Med., 11, 71, 10.1186/s13073-019-0684-0 Martín-López, 2017, Mutation of TGFβ-RII eliminates NSAID cancer chemoprevention, Oncotarget, 9, 12554, 10.18632/oncotarget.23792 McNeil, 2021, Effect of aspirin on cancer incidence and mortality in older adults, J. Natl. Cancer Inst., 113, 258, 10.1093/jnci/djaa114 Miggelbrink, 2021, CD4 T-cell exhaustion: does it exist and what are its roles in cancer?, Clin. Cancer Res., 27, 5742, 10.1158/1078-0432.CCR-21-0206 Moller, 2017, Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database, Gut, 66, 464, 10.1136/gutjnl-2015-309675 Muller, 2019, Effective identification of lynch syndrome in gastroenterology practice, Curr. Treat. Options Gastroenterol., 17, 666, 10.1007/s11938-019-00261-2 Muller, 2020, Precision treatment and prevention of colorectal cancer-hope or hype?, Gastroenterology, 158, 441, 10.1053/j.gastro.2019.09.046 O'Donnell, 2018, MHCflurry: open-source class I MHC binding affinity prediction, Cell Syst., 7, 129, 10.1016/j.cels.2018.05.014 Olave, 2022, Mismatch repair deficiency: the what, how and why it is important, Genes Chromosomes Cancer, 61, 314, 10.1002/gcc.23015 Ott, 2020, A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer, Cell, 183, 347, 10.1016/j.cell.2020.08.053 Ottensmeier, 2017, Cancer vaccines Overman, 2021, 410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI), J. ImmunoTher.Cancer, 9, 10.1136/jitc-2021-SITC2021.410 Ozirmak Lermi, 2022, Comparative molecular genomic analyses of a spontaneous rhesus macaque model of mismatch repair-deficient colorectal cancer, PLoS Genet., 18, 10.1371/journal.pgen.1010163 Pastor, 2021, Immunology of lynch syndrome, Curr. Oncol. Rep., 23, 96, 10.1007/s11912-021-01085-z Perez-Carbonell, 2012, Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer, Gut, 61, 865, 10.1136/gutjnl-2011-300041 Podaza, 2020, Evaluation of T-cell responses against shared melanoma associated antigens and predicted neoantigens in cutaneous melanoma patients treated with the CSF-470 allogeneic cell vaccine plus BCG and GM-CSF, Front. Immunol., 11, 1147, 10.3389/fimmu.2020.01147 Randrian, 2021, 13 Raybould, 2022, Computationally profiling peptide:MHC recognition by T-cell receptors and T-cell receptor-mimetic antibodies, Front. Immunol., 13 Reble, 2017, VarScan2 analysis of de novo variants in monozygotic twins discordant for schizophrenia, Psychiatr. Genet., 27, 62, 10.1097/YPG.0000000000000162 Reuschenbach, 2014, A multiplex method for the detection of serum antibodies against in silico-predicted tumor antigens, Cancer Immunol. Immunother., 63, 1251, 10.1007/s00262-014-1595-y Reuschenbach, 2010, Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome, Fam. Cancer, 9, 173, 10.1007/s10689-009-9307-z Reyes-Uribe, 2021, Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa, Gut, 70, 555, 10.1136/gutjnl-2020-320946 Reynisson, 2020, NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data, Nucleic Acids Res., 48, W449, 10.1093/nar/gkaa379 Richman, 2019, Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade, Cell Syst., 9, 375, 10.1016/j.cels.2019.08.009 Ripberger, 2003, Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene, J. Clin. Immunol., 23, 415, 10.1023/A:1025329819121 Roudko, 2020, Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors, Cell, 183, 1634, 10.1016/j.cell.2020.11.004 Rubinsteyn, 2017, Isaac hodes, julia Kodysh, and jeffrey hammerbacher Sahin, 2017, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature, 547, 222, 10.1038/nature23003 Sasidharan Nair, 2020, 8 Saxena, 2021, Therapeutic cancer vaccines, Nat. Rev. Cancer, 21, 360, 10.1038/s41568-021-00346-0 Schoenberger, 1998, T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, Nature, 393, 480, 10.1038/31002 Schwitalle, 2008, Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers, Gastroenterology, 134, 988, 10.1053/j.gastro.2008.01.015 Schwitalle, 2004, Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells, Cancer Immun., 4, 14 2021 Shao, 2020, High-Throughput prediction of MHC class I and II neoantigens with MHCnuggets, Cancer Immunol Res, 8, 396, 10.1158/2326-6066.CIR-19-0464 Shelton, 2021, Engineering approaches for studying immune-tumor cell interactions and immunotherapy, iScience, 24, 10.1016/j.isci.2020.101985 Singh, 2017, Emerging concepts in TCR specificity: rationalizing and (maybe) predicting outcomes, J. Immunol., 199, 2203, 10.4049/jimmunol.1700744 SRL Stranzl, 2010, NetCTLpan: pan-specific MHC class I pathway epitope predictions, Immunogenetics, 62, 357, 10.1007/s00251-010-0441-4 Surmann, 2015, Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer, Cancer Immunol. Immunother., 64, 357, 10.1007/s00262-014-1638-4 Szolek, 2014, OptiType: precision HLA typing from next-generation sequencing data, Bioinformatics, 30, 3310, 10.1093/bioinformatics/btu548 Tan, 2022, Nonsense-mediated RNA decay: an emerging modulator of malignancy, Nat. Rev. Cancer, 22, 437, 10.1038/s41568-022-00481-2 Te, 2022 Therkildsen, 2021, An update on immune checkpoint therapy for the treatment of lynch syndrome, Clin. Exp. Gastroenterol., 14, 181, 10.2147/CEG.S278054 Tran, 2016, T-cell transfer therapy targeting mutant KRAS in cancer, N. Engl. J. Med., 375, 2255, 10.1056/NEJMoa1609279 Treangen, 2011, Repetitive DNA and next-generation sequencing: computational challenges and solutions, Nat. Rev. Genet., 13, 36, 10.1038/nrg3117 Turajlic, 2017, Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis, Lancet Oncol., 18, 1009, 10.1016/S1470-2045(17)30516-8 Umar, 2004, Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J. Natl. Cancer Inst., 96, 261, 10.1093/jnci/djh034 Vasen, 1999, New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC, Gastroenterology, 116, 1453, 10.1016/S0016-5085(99)70510-X Verdon, 2021, 13 Vilar, 2010, Microsatellite instability in colorectal cancer-the stable evidence, Nat. Rev. Clin. Oncol., 7, 153, 10.1038/nrclinonc.2009.237 Walkowska, 2019, Immunoprofiles of colorectal cancer from Lynch syndrome, OncoImmunology, 8, 10.1080/2162402X.2018.1515612 Wang, 2022, Lipid nanoparticles for mRNA delivery to enhance cancer immunotherapy, Molecules, 27 Wang, 2021, mRNA vaccine: a potential therapeutic strategy, Mol. Cancer, 20, 33, 10.1186/s12943-021-01311-z Watts, 2005, TNF/TNFR family members in costimulation of T cell responses, Annu. Rev. Immunol., 23, 23, 10.1146/annurev.immunol.23.021704.115839 Willis, 2020, Immune activation in mismatch repair-deficient carcinogenesis: more than just mutational rate, Clin. Cancer Res., 26, 11, 10.1158/1078-0432.CCR-18-0856 Woerner, 2003, Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes, Oncogene, 22, 2226, 10.1038/sj.onc.1206421 Wolfl, 2007, Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities, Blood, 110, 201, 10.1182/blood-2006-11-056168 Wylie, 2021, 13 Xie, 2023, Neoantigens: promising targets for cancer therapy, Signal Transduct. Targeted Ther., 8, 9, 10.1038/s41392-022-01270-x Xiong, 2022, Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles, J. Extracell. Vesicles, 11, 10.1002/jev2.12243 Yadav, 2014, Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing, Nature, 515, 572, 10.1038/nature14001 Yurgelun, 2012, Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps, Cancer Prev. Res., 5, 574, 10.1158/1940-6207.CAPR-11-0519 Zhang, 2022, B2M and JAK1/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy, J. Immunother., 45, 187, 10.1097/CJI.0000000000000417 Zhang, 2019, Advances in mRNA vaccines for infectious diseases, Front. Immunol., 10, 594, 10.3389/fimmu.2019.00594 Zheng, 2022, Neoantigen: a promising target for the immunotherapy of colorectal cancer, Dis. Markers Zhou, 2019, pTuneos: prioritizing tumor neoantigens from next-generation sequencing data, Genome Med., 11, 67, 10.1186/s13073-019-0679-x Zhou, 2022, Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy, Biomed. Pharmacother., 156, 10.1016/j.biopha.2022.113790 Zhu, 2021, Neoantigen-reactive T cell: an emerging role in adoptive cellular immunotherapy, MedComm, 2, 207, 10.1002/mco2.41